Candel Therapeutics Inc. has released a corporate presentation highlighting key developments in its oncology pipeline. The company reported positive results from a phase 3 randomized placebo-controlled clinical trial of its lead candidate, CAN-2409, in localized, intermediate- to high-risk prostate cancer. Positive overall survival data were also observed in randomized phase 2a clinical trials of CAN-2409 for borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer. The presentation notes ongoing precommercialization activities for CAN-2409 and outlines the company’s financial position, including $87.0 million in cash and cash equivalents as of September 30, 2025, and a term loan facility of up to $130 million. Additional upcoming clinical milestones in prostate cancer, non-small cell lung cancer, and recurrent high-grade glioma are detailed. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.